comparemela.com

Latest Breaking News On - Reported outcome - Page 2 : comparemela.com

Ipsen updates on E U Marketing Authorisation Application for odevixibat in Alagille syndrome

Positive opinion from Committee for Medicinal Products for Human Use recommending approval of Bylvay® (odevixibat) based on Phase III ASSERT clinical-trial data in Alagille syndrome (ALGS) already received in July 2023Committee for Orphan Medicinal Products confirms a negative opinion of its review recommending not to maintain the orphan designation for Bylvay in ALGSIpsen plans to submit a new Marketing Authorisation Application for the treatment of ALGS by the end of 2023 under a new brand nam

Investegate | Company Announcement

Newswire & Press Release / Ipsen Updates on E U Marketing Authorisation Application for Odevixibat in Alagille Syndrome - Pharma / BioTech / Nutrition - IPSEN Group

Newswire & Press Release / Ipsen Updates on E U Marketing Authorisation Application for Odevixibat in Alagille Syndrome - Pharma / BioTech / Nutrition - IPSEN Group
newswiretoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswiretoday.com Daily Mail and Mail on Sunday newspapers.

Newswire & Press Release / Ipsen Updates on E U Marketing Authorisation Application for Odevixibat in Alagille Syndrome - Pharma / BioTech / Nutrition - IPSEN Group

Newswire & Press Release / Ipsen Updates on E U Marketing Authorisation Application for Odevixibat in Alagille Syndrome - Pharma / BioTech / Nutrition - IPSEN Group
newswiretoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswiretoday.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.